NCT05830097 2024-08-26
A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors
Coherent Biopharma (Hefei) Co., Ltd.
Phase 1/2 Unknown
Clinical Trials
10 trialsNCT06008366 2023-09-13
A Phase 1/2 Study of 7MW3711 in Advanced Solid Tumors
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1/2 Unknown
NCT06008379 2023-09-13
A Study of 7MW3711 in Subjects With Advanced Solid Tumors
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1/2 Unknown
NCT05845138 2023-08-01
A Study of SHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression.
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2 Unknown
NCT05742750 2023-02-24
A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer
Sun Yat-sen University
Phase 1/2 Unknown
NCT04506138 2021-12-14
Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma
Zhejiang Cancer Hospital
Phase 1/2 Unknown
NCT03989310 2020-12-23
An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic Pancreatic Cancer
Chinese PLA General Hospital
Phase 1/2 Unknown
NCT03946917 2020-05-12
JS001 Combined With Regorafenib in Patients With Advanced Colorectal Cancer
Sun Yat-sen University
Phase 1/2 Unknown
NCT04213898 2019-12-30
SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer
Henan Cancer Hospital
Phase 1/2 Unknown
NCT04004234 2019-07-09
A Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic BTC
Chinese PLA General Hospital
Phase 1/2 Unknown